Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And yet NO ONE buys shares or makes an offer. Meanwhile Bal is looking to exit (supposedly). Warren, are you not aware? How about you, Carl?
This is a market that Sintx can tap that Implex Hydrocel couldnt touch showing Sintx IP is worth more than $232m Zimmer paid for Implex.
Oops, may have 'guessed' wrong, as sells outpaced buys today almost 2 to 1 on a little higher volume. Ah, such is life in pennyville.
Feds to spend millions to contain bird flu outbreak amid testing lag
Federal officials are scrambling to track the virus. But they’ve struggled to gain access to farms to collect data.
The federal government will spend millions to stem the spread of avian influenza in the nation’s dairy herds to keep the virus from mutating and spreading among humans, officials said Friday.
The investment comes after the federal government drew fire from public health experts for not testing enough cattle or workers exposed to infected herds, which they worry endangers the ability of the U.S. to rapidly respond if the virus mutates. Under the new plan, the government will compensate impacted farmers for costs associated with the virus and juice efforts to track and trace the virus.
The CDC has published guidelines for people working closely with infected animals and this week urged states to facilitate the distribution of protective gear like aprons, gloves and goggles. Still, public health experts and farmworker advocates fear that workers, who are likely the first line of defense to prevent the spread of the virus among humans, are not adequately protected.
Surgical Gowns, Drapes, and Curtains
From surgical drapes to gowns to antimicrobial bedsheets to medical tools, we are working with our partners to revolutionize their product lines with FleX-SN AP. This will help minimize the chance for healthcare-associated infections, which account for hundreds of thousands of deaths each year in the U.S. alone28.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
24/7 trying to force a bs prediction on a chart. Damn he is fos Hope MAD did not fall for his attempt
To shake him down for his scam
TA, not accurate as usual but your post, and repeated mentioning of this, looks like an indirect threat if i were to contact the SEC about whats been going on with SINT. Concerned about something are we? Oh thats interesting you have all my posts like Madg does? You know that ST & Ihub retain that information dont you? You dont need to keep them. But your continued threats only show your fear. Yes i posted this for reference purposes.
24/7 i have all your post from here and over there. And the post about the private jets that mysteriously was deleted. You have been pumping telling people to buy this pos all the way down. Sec yes please do lol
You lying to scam people into this pos has cost people their life saving
Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
A 50% drop after announcement of an offering is not normal. 50% drop post offering is not normal either but is more common with certain kinds of stocks. You can see from the chart below this behavior is new to SINT.
Neither phenomenon were the result of anything negative that was happening with Sintx. The fact that i was warned to sell before this began further shows this was done on purpose. The chart you like to post TA actually shows theres something unnatural going on with the stock. Before the 100:1 RS SINT traded pretty well in that channel, which is a clue in itself someones have been manipulating the stock. The accelerated dropping of the stock (in the yellow area) while revenue was growing for Sintx, makes it very obvious. Thats what the SEC needs to investigate.
https://i.imgur.com/xMRDE8n.jpeg
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
$SINT This Top-Performing Stock Has the Potential to Rise 1000% in no time
$SINT EXPLODING 0.0463 +0.0026 (+5.9497%)
$SINT getting in to the beast mode going to breakout soon
One thing particularly interesting since the 2022 RS was the fact that with each announcement of offering the price of the stock would immediately drop 50% or so. That's before such an offering was even closed. Before new shares hit market. Then, because of the exact mechanism I described in my last post the price would be naked shorted another 50% post offering. So if the price was at 50 cents on announcement of a forthcoming offering, offering price then occurred at .25, and then closed out at 12.5ish post offering. There it stood for awhile until the next halving at 4.7 cents.
No negative news was released by the company to justify these drops, it just dropped because it could. However it did this repeatedly showcasing a pattern which shows purpose/collusion/manipulation. The one major anomaly was when the stock was trading in the 8-9 dollar range and the offering was announced, for some reason at 5.6. Look at the trading history. The stock price hit a high of $12.14 in the 3 trading days before the offering price was announced at 5.6. Then the next day the price halved the previous days low to the low 3's. Funds naked shorted into that offering from as high as 12.14. SEC needs to investigate the trading that has occurred in regards to SINT and the short & distorting thats gone on via social media.
Correlating Short/Naked Short data with each offering should show something interesting.
For whatever reason funds that buy the offerings mainly use naked short method to convert their preferred/warrants. So they naked short above the price of the offering and fill that naked share via converting their preferred/warrants. In part this is done to prevent from exceeding the ownership maximum requirements. Still why cant the price increase to better reflect Sintx IPs value and then convert? For some reason, all funds seem to only naked short and convert.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
garbage can penny stocks do reverse splits. Real companies do forward splits
The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.
Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.
We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.
In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.
Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
So far all week theres been a high percentage of shorting before next weeks RS vote. However the amount of shares available to borrow by IBR continues to grow suggesting accumulation along with the higher short volume of ~64% via dark pool with a droping percent via Montreal Stock Exchange. Most of the shares trade via Q = NASD ADF with the remaining trading via the N = Montreal Stock Exchange.
Trade Facility Date Symbol Short Volume Short Exempt Volume Total Volume Market
NQTRF 2024-05-08 SINT 4376860 34549 6848710 Q 63.91%
NYTRF 2024-05-08 SINT 293341 0 698698 N 41.98%
NQTRF 2024-05-07 SINT 3842217 742286 5994330 Q 64.10%
NYTRF 2024-05-07 SINT 447136 49 951888 N 46.97%
NQTRF 2024-05-06 SINT 3593505 233433 5447246 Q 65.97%
NYTRF 2024-05-06 SINT 336846 202 716017 N 47.04%
https://www.finra.org/finra-data/browse-catalog/short-sale-volume-data
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Watching this
$150 down to 4 cents?? wtf?
$1m market cap and 22m OS?
And that’s because no one I mean no one trusts anything the cdc says. The new head is a liar just like wolensky!
In my previous post i said that if Sintx was properly valued then there wouldnt be as many offerings, shares issued per offering, or reverse splits. To show just how much Sintx Si3n4 is worth, one need only look at a comparable company Implex, acquired in 2003, to see how much Sintx Si3N4 is worth in the few markets that Implex Hydrocel (Zimmer's Trabecular Metal) is used in. Keep in mind that Si3n4 brings superior benefits with it compared to that of Trabecular Metal (biodegradable, antimicrobial, more osseointegrative, can be imbued and used as a coating in/on other materials), has a larger market reach (armor, defense, aerospace, industrial, antipathogenic, other medical products), and has not been mired in recalls and lawsuits.
I go into why Sintx is so undervalued in my previous post. Even then, it doesnt explain why Sintx marketcap is 1/20th of Implex's value when its IP is worth more than Implex's.
Total acquisition costs of Implex was $108m upfront + $124.1 (96m+28.1) in cash earn-out payments from 2004-2006 for a grand total of $232.1m. Sintx tried to IPO for a valuation of around $225m in 2007 when it only had spinal product candidates and hip/knee candidates in early stages of R&D.
The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.
Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.
We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.
In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.
Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Look at that, ive claimed (with evidence) that Tesla is a fake it until it makes it scam on a bigger scale than Theranos and now investigators are investigating Tesla for securities and wire fraud. Its just a matter of time until Sintx is proven not to be a money printing scam even though hedge funds use SINT as one; more on this below.
As i said in my previous post, Sintx is not the scam. It has real products/product candidates, no real debt, minimal cash burn considering how expensive R&D is, and has several strategic partnerships with large companies. You want to see a real corporate scam in action, i post about it in the following link. Its a bigger scam than that of Theranos. "Consumer fraud on a massive scale".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174317282
However i cannot argue against the fact that SINT is being used as a "money printing scam". Ive said that if Sintx was properly valued and SINT reflected that value, then there would not be as many offerings, as many shares "printed" with each offering, and no Reverse Splits. However because Sintx is not properly valued and thus SINT along with it, shorting and naked shorting drives the price lower and thus with each new offering prints a ton more shares then would have occurred otherwise had the price not been shorted into the offering.
Who is making the easy money shorting every offering before and after its closing? Who benefits from massive expansion of shares from every offering? Who benefits shorting before and after every RS? Who needs SINT to print millions more shares to close out their naked short positions? The hfunds that buy the offerings and hold those naked short positions thats who and all those regulars that short with them! They are the ones making easy money using SINT as a "money printing scam". They take advantage of the fact that SINT is insanely undervalued, something i believe they helped create, and the fact that Sintx has to tap markets to fund its R&D. However Sintx continues to develop very valuable IP with those dollars it receives to fund R&D.
Just One Human Is Infected by Bird Flu in the US. More Cases Are Likely
(Bloomberg) -- It’s spreading rapidly among cows. It’s also infecting skunks, mountain lions and red foxes.
Yet as the highly contagious avian flu affects mammals across the US, just one human case has been reported so far.
But that’s probably only because there is extremely limited testing of people underway to detect it. State governments and farm owners have kept Centers for Disease Control and Prevention teams from conducting on-the-ground investigations that would offer a fuller picture of the prevalence of the virus in humans.
That threatens to impair federal officials’ response to an outbreak that many experts view as the biggest test for pandemic readiness systems since Covid-19. The recent patient is recovering after experiencing eye redness as their sole symptom. However, avian flu typically kills half the people known to have been infected, hinting at the danger it poses if it were to spread widely.
The CDC does not have authorization to carry out on-the-ground investigations without an invitation, and the states that have confirmed infected cattle say they have not made such an overture to the agency.
The development of FleX-SN AP applications like masks, medical gowns, IT devices, air filters, and much more, aims to reduce and prevent the spread of viral diseases. FleX-SN AP can be used in a variety of composites for a multitude of applications.
Relatively few people have caught the virus so far, but it has had a high mortality rate in those that do: more than 50% of people known to become infected have died.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
$SINT take an advantage of this opportunity and load up
Pre-Market 0.0447 0.00 (0.00%)
Although I'm not a day trader nor a pumper or dumper, it does seem the 'buys' continue to beat the 'sells' most days here, including today by a decent margin. My guess, Sint still can squeeze out another 20-25% gain just on momentum. Any news of course, can push it either way.
Electromagnetic Interference Shielding Properties of SiC Ceramic Matrix
Composite Reinforced by Three-dimensional Silicon Carbide Nanowire Network
Due to the intensive growing application of electronic devices, the harm of EMWs emitted from electronic devices to human health cannot be ignored [1-4] . Also, electromagnetic interference (EMI) can make electronic devices difficult for normal operation. To reduce the damage of EMI to the human body and electronic devices, materials are designed to shield or weaken EMI [5] . The shielding material can cut down the EMWs emitted by electronic equipments and prevent the EMWs from scattering, which can ensure a relatively independent working environment and prevent the information from leaking by the EMWs.
However, the properties of high density, easy to be oxidized and corroded significantly limit the application of metal in electromagnetic shielding material.
In recent years, one-dimensional nanomaterials with unique properties have attracted the attention of researchers. Especially, SiCNWs possess many unpaired chemical bonds on the surface than SiC f , which can be polarized in
electromagnetic fields to consume the EMWs [8-12] . So SiCNWs with the unique one-dimensional structure own excellent electromagnetic absorption performance, and the construction of a 3D spatial network is expected to further enhance the EMI SE [13-16] . The introduction of SiCNWs into composites can effectively improve the EMI shielding performance of the composites
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
SINTX is excited to be exhibiting at the Hypersonic Innovation Conference in Dayton, OH this week. Come see us in Booth 207 to learn about our solutions based on C/SiC CMCs, Silicon Nitride, and Ceramic Additive Manufacturing.
The 3rd Annual Hypersonic Innovation Conference is America's official hypersonics event, featuring Senior military leaders, acquisition authorities, & technical experts from across industry & academia. This “town-hall” style forum will offer attendees from military, government, industry, and academia a wide range of next-generation products and services that are enabling the U.S. military to design, test, manufacture, and scale hypersonic missiles in an era of Strategic Competition.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
$SINT keeps rising 0.0455
+0.0035 (+8.33%)
$SINT 0.042 getting ready to run big money coming in
Hey NoneYa, you may wanna update your facts. While Sintx is focused primarily on Si3N4 with Zirconia thrown in for Dental, TA&T brought with it other ceramics just like Sintx Armor!
SINTX has a long history of developing composites and coatings for extreme environments. Our 30 years of experience has allowed us to gain expertise with both C and SiC fibers, debond coatings including carbon and SiC, dozens of different options for the composition and the production process for the ceramic matrix, and a wide array of final barrier coatings.
Our Ceramic Matrix Composite (CMC) experience initially was focused on Carbon/SiC and SiC/SiC based formulations, but this material family has a wide array of options which tailor the properties such as density, strength, oxidation resistance, and wear resistance.
This is why CMCs are so important in airplane engines as they could address this issue:
NTSB: Burning engine, ‘fire on board,’ preceded fatal plane crash near Fairbanks
The report states that an eyewitness saw the plane shortly after takeoff with the far left engine not running. The eyewitness also reported seeing a white plume of smoke coming from that engine.
Surveillance cam video from a property near the crash site shows the plane flying low, then a burst of fire from the left wing before the plane swiftly turns downward and falls toward the ground, going out of sight from the camera view behind a patch of trees.
This proposed AD was prompted by a report that certain exterior fairing panels on the top of the engine nacelle and strut (the thumbnail fairing and mid strut fairing panels) may not have the quality of electrical bonding necessary to ensure adequate shielding of the underlying wiring from the electromagnetic effects of lightning strikes or high intensity radiated fields (HIRF), which could potentially lead to a dual engine power loss event from a critical lightning or HIRF exposure event
CERAMIC MATRIX COMPOSITES & COATINGS
CMCs are in high demand from major OEMs for aerospace, heat exchangers, turbine engines, hypersonic-supersonic vehicles, and related applications.
CMC Coatings
Recently developed oxidation resistant coatings for CMCs that extend their useful application to extreme temperatures.
Electromagnetic wave absorption and mechanical properties of silicon carbide fibers reinforced silicon nitride matrix composites
Might want to look $SINT she is up again today on pre market
Now Zimmer paid $232m in total for Implex's Hydrocel material which it calls Trabecular Metal. However its paid out so much more in legal costs and lawsuit settlements. At one time i had estimated the costs to being over north of a billion.
Also trabecular metal was originally used in Spine and Hip/Knee, but it grew to include dental, foot, & shoulder implants. All places Sintx Si3N4 can be used while having superior antibacterial and osteointragrative properties which should prevent such loosening issues. As far as ive seen every product that has had Trabecular Metal in it has suffered a recall and loosening.
3D printing of Si3n4 is important to help reduce Si3N4's 1 major drawback, modulus of elasticity which prevents the material from being used in certain applications like femoral stems. Still Sintx has its coating tech and can also imbue plastic implants with Si3N4 thus expanding Si3N4 market potential. This is why it can be used for so many different medical applications. There are other reasons to want to use ceramics over metals as metals amplify EM radiation (Natural and manmade) and thus increase dis-ease. More on that at the bottom of post.
Notice those bashing Sintx & Si3n4 have to resort to methods of disinformation in their posts like employing strawman argument or Reductio Ad Absurdum.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
They should use at least 50% of the proceeds from recent offerings to give Sonny a farewell bonus for having such a low salary. He only collected ~$4mm during his time as ceo for his stellar performance.
The employees should work for free honestly. This product is basically flex seal on steroids and solves every problem known to mankind. The audacity of expecting to be paid and hindering the growth of this product is criminal due to taking away valuable capital so they can have more patents.
Buybacks or giving more money to Sonny are the only two clear choices.
Total acquisition costs of Implex was $108m upfront + $124.1 (96m+28.1) in cash earn-out payments from 2004-2006 for a grand total of $232.1m. Sintx tried to IPO for a valuation of around $225m in 2007 when it only had spinal product candidates and hip/knee candidates in early stages of R&D.
Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.
We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.
In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.
The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Was their news what happened
Cuz pow bang zoom to the moon
Let's see..meet payroll, or buyback stock?
which will it be?
Do you think they did all of the recent share offerings to start buying back stock? What’s your outlook here, big money??
Don’t sit on bid all day hit the ask and start making money today
$SINT - Sintx Technologies, Inc. Setting up for big run
Folks $SINT exploding she is heading .10+
If he cared about investors at all, or dare I say, even the company, he would take himself out of the role of ceo.
The least he should do is step down as the ceo, and look for someone who knows the ins and outs of running a public company.
To the potential investor, I say WAIT! Wait until a takeover, an ouster of present ceo, OR large investors begin to take notice. WAIT until present management begins to heavily invest. Until then, it's just a game as it has always been
come on Sonny - make up for years of shareholder abuse - go out in a blaze of glory - sell this sucker for $100MM!!!!!!
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
$SINT huge a buying pressure happening again
Anyone that sold out $SINT now buying back in at higher price she is running now
Sonny is responsible for the massive expansion in IP during his tenure. He laid the foundation. That hardly qualifies as a cancer. New CEO can monetize it. Then if Sonny stays on as Chairman he can sell the company which he implied was the plan. The main problem has been the market hasnt properly valued Sintx IP...at all (currrent value = worthless as the current market cap is below tangible assets). So when that IP begins to be monetized there will be a massive increase in valuation for SINT because suddenly all that value will have to be recognized. What should have occurred is the value should have been reflected with time/risk factored in and slowly grown from there. That has never happened and thus the market & funds are the cancer as ive been saying.
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.
now is the time for this POS company to finally monetize all the accumulated IP from years of successful lab & research (and commercial failure) and SELL THE F***ING COMPANY
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
As madg stated, the "cancer still remains." I agree. There's nothing to celebrate yet, other than an announcement, and we all know how that can go. Right now, it would appear retailers are walking with trepidation, as are the banks and funds, as well as insiders. Time will tell....
As much as you guys complained about Sonny as the CEO, why isnt there more celebrating and why isnt the stock going up?
$SINT can go up 100% blink of eye take an advantage and load up folks
What does that have to do with anything? If you want to post about Sonny being on a board of trustees then this makes more sense:
Point 3: Zimmer Biomet CEO David Dvorak, in 2016 and Sintx CEO Dr Bal join OREF at the same time. Thus some hobnobbing would ensue for however long the two were on the board of trustees for.
In addition, the trustees welcome to the board: Jeffrey S. Abrams, MD (Princeton, NJ); Christopher R. Adams, MD (Naples, FL); B. Sonny Bal, MD, JD, MBA (Columbia, MO); Paul C. Collins, MD (Boise, ID); David C. Dvorak, JD (Warsaw, IN); James R. Ficke, MD (Baltimore, MD); and Joshua J. Jacobs, MD (Chicago, IL).
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
BOARD ADDITION: DR. SONNY BAL
November 1, 2023
in Foundation updates
At the Thompson Foundation board meeting last week, Dr. Sonny Bal was elected to the board of directors. Dr. Bal is CEO & President of SINTX Technologies, an original equipment manufacturing (OEM) ceramics company headquartered in Salt Lake City that develops and commercializes silicon nitride ceramics for medical and non-medical applications. Dr. Bal was an MU professor of Orthopaedic Surgery from 1999-2017 and served as an adjunct professor of Material Sciences at Missouri S&T. He has researched and published extensively in ceramic science and serves on the editorial boards of peer-refereed journals. He is also a licensed attorney who co-founded the Bal Brenner law firm in North Carolina.
In addition to his JD from Mizzou, he holds a BS in Genetics from UC Davis, an MD from Cornell University, an MBA from Northwestern University, and a PhD in Materials Engineering from the Kyoto Institute of Technology. He received fellowship training in joint replacement surgery at Massachusetts General Hospital, Harvard University, and he did residencies at UC San Francisco and UMKC. He met his spouse, Dana Bal, M.D., when she was in medical school at UMKC. The Bal family calls Columbia home.
Welcome, Dr. Bal!
Source???
Or random speculation???
Followers
|
241
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
41259
|
Created
|
02/13/14
|
Type
|
Free
|
Moderators Atlanta1 Tesla thru the roof |
https://www.youtube.com/watch?v=j94SgeyCh3M
(AMDA) Amedica Corp. - NASDAQ
RECENT NEWS
https://www.youtube.com/watch?v=hxbj7Sq7W94
https://www.youtube.com/watch?v=j94SgeyCh3M
https://www.youtube.com/watch?v=KbU47COpXx8
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |